Background Evidence on whether the therapeutic effect and good safety profile of onabotulinumtoxinA (Botox®) in chronic migraine (CM) patients is maintained over long term …
S Quintas, D García-Azorín, P Heredia… - Pain …, 2019 - academic.oup.com
Objective Long-term real-life studies have supported a cumulative effect of OnabotulinumtoxinA (OnabotA) for the prophylactic treatment of chronic migraine (CM) …
H Mimeh, AM Fenech Magrin, S Myers… - Aesthetic surgery …, 2019 - academic.oup.com
Background Migraine is a severe, disabling condition, ranked by World Health Organization as the sixth highest cause of disability worldwide. It greatly affects patients' quality of life …
L Santana, C Liu - The Journal of Pediatric Pharmacology …, 2021 - meridian.allenpress.com
OBJECTIVES Prevalence of chronic migraine in children can reach 7.7%, causing decreased school performance, difficulty with extracurricular activities (including sports …
A Gonzalez-Martinez, I Muro, S Quintas… - Gastroenterología y …, 2024 - Elsevier
Background The gut-brain axis describes a complex bidirectional association between neurological and gastrointestinal (GI) disorders. In patients with migraine, GI comorbidities …
J Odell, C Clark, A Hunnisett, OH Ahmed… - Chiropractic & Manual …, 2019 - Springer
Introduction Chronic migraine is a largely refractory condition affecting between 1 and 2.2% of the overall population worldwide, with females more affected than males. There are also …
Chronic migraine (CM) is a leading cause of disability, worldwide. Research examining the systemic effects of CM is scant. Specifically, little is understood about the effects of migraine …
T Mallick-Searle - Holistic Pain Management in Pregnancy: What RNs …, 2022 - Springer
The practice of pain management over the past two decades has shifted from a biomedical model where patients are managed primarily with pharmacotherapies, to a biopsychosocial …